Search Results - "RAOUL, J. L"

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization by Raoul, J.-L, Sangro, B, Forner, A, Mazzaferro, V, Piscaglia, F, Bolondi, L, Lencioni, R

“…Summary Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However,…”
Get full text

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study by Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D.R., Ishak, K.J., Raymond, E.

“…In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved…”
Get full text

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) by Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A.

“…Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse. Patients…”
Get full text

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer by Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., Esterni, B., Genre, D., Moureau-Zabotto, L., Giovannini, M., Seitz, J-F., Delpero, J-R., Turrini, O., Viens, P., Raoul, J-L.

“…Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of…”
Get full text

Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009 by Adam, R., Haller, D.G., Poston, G., Raoul, J.-L., Spano, J.-P., Tabernero, J., Van Cutsem, E.

“…Metastatic colorectal cancer is a particularly frequent and severe cancer. Patients die mainly from metastatic disease; however, the survival of these patients…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

Use of chemotherapy near the end of life: what factors matter? by Rochigneux, P., Raoul, J.L., Beaussant, Y., Aubry, R., Goldwasser, F., Tournigand, C., Morin, L.

“…Use of chemotherapy near the end of life in patients with metastatic cancer is often ineffective and toxic. Data about the factors associated with its use…”
Get full text

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601 by Ferrand, F, Malka, D, Bourredjem, A, Allonier, C, Bouché, O, Louafi, S, Boige, V, Mousseau, M, Raoul, J.L, Bedenne, L, Leduc, B, Deguiral, P, Faron, M, Pignon, J.P, Ducreux, M

“…Abstract Objective To assess the impact of primary tumour resection on overall survival (OS) of patients diagnosed with stage IV colorectal cancer (CRC)…”
Get full text

Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) by Pernot, S, Artru, P, Tougeron, D, Montérymard, C, Smith, D, De La Fouchardière, C, Raoul, J-L, Dahan, L, Guimbaud, R, Michel, P, Jouve, J-L, Pellerin, O, Taieb, J

Get full text

Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions by Heo, J., Cheng, A.-L., Raoul, J.-L., Peck-Radosavljevic, M., Kudo, M., Nakajima, K., Bayh, I., Lin, S.-M., Lee, H.C.

Get full text

Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada by Raoul, J.-L., Decaens, T., Burak, K., Koskinas, J., Villadsen, G.E., Heurgue-Berlot, A., Bayh, I., Cheng, A.-L., Kudo, M., Lee, H.C., Nakajima, K., Peck-Radosavljevic, M.

Get full text

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial by BOIGE, V, RAOUL, J.-L, PIGNON, J. P, BOUCHE, O, BLANC, J.-F, DAHAN, L, JOUVE, J.-L, DUPOUY, N, DUCREUX, M

“…Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to…”
Get full text

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials by Collette, S., Bonnetain, F., Paoletti, X., Doffoel, M., Bouché, O., Raoul, J.L., Rougier, P., Masskouri, F., Bedenne, L., Barbare, J.C.

“…The objective of this study was to assess the performance of three staging systems [Okuda, Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic…”
Get full text

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial by Bachet, J.B., Lucidarme, O., Levache, C.B., Barbier, E., Raoul, J.L., Lecomte, T., Desauw, C., Brocard, F., Pernot, S., Breysacher, G., Lagasse, J.P., Di Fiore, F., Etienne, P.L., Dupuis, O.J.M., Aleba, A., Lepage, C., Taieb, J., Dahan, L., Auby, D., Khemissa, F., Ghiringhelli, F., Nguyen, S., Bedjaoui, A., Terrebonne, E., Thaury, J., Baconnier, M.

“…The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of…”
Get full text

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer by Conroy, T, Yataghène, Y, Etienne, P L, Michel, P, Senellart, H, Raoul, J L, Mineur, L, Rives, M, Mirabel, X, Lamezec, B, Rio, E, Le Prisé, E, Peiffert, D, Adenis, A

“…Background: Concurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement is still needed. A randomised…”
Get full text

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma by Ducreux, M., Rougier, P., Pignon, J.-P., Douillard, J.-Y., Seitz, J.-F., Bugat, R., Bosset, J.-F., Merouche, Y., Raoul, J.-L., Ychou, M., Adenis, A., Berthault-Cvitkovic, F., Luboinski, M.

“…Background: Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma, but patient survival and quality of life has improved with this…”
Get full text

131-iodine Lipiodol therapy in hepatocellular carcinoma by Raoul, J-L, Boucher, E, Roland, V, Garin, E

“…Hepatocellular carcinoma (HCC) is a major health concern worldwide. Several therapeutic options are available, but transplantation is the only curative option;…”
Get full text

Carcinome hépatocellulaire : nous sommes à l’aube d’une nouvelle époque by Raoul, J. -L.

Get full text

Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial by MICHEL, P, ADENIS, A, HELLOT, M. F, PROD'HOMME, S, PAILLOT, B, DI FIORE, F, BOUCHER, E, GALAIS, M. P, DAHAN, L, MIRABEL, X, HAMIDOU, H, RAOUL, J. L, JACOB, J. H

“…A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with…”
Get full text

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group by Briasoulis, E, Pavlidis, N, Terret, C, Bauer, J, Fiedler, W, Schöffski, P, Raoul, J-L, Hess, D, Selvais, R, Lacombe, D, Bachmann, P, Fumoleau, P

“…The activity of glufosfamide (β-d-glucopyranosyl-N,N′-di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre,…”
Get full text